People: Genmark Diagnostics Inc (GNMK.W)
GNMK.W on CBOE When Trading NASDAQ Global Select Market
15.28USD
17 May 2013
15.28USD
17 May 2013
Price Change (% chg)
$0.03 (+0.20%)
$0.03 (+0.20%)
Prev Close
$15.25
$15.25
Open
$15.25
$15.25
Day's High
$15.28
$15.28
Day's Low
$15.25
$15.25
Volume
200
200
Avg. Vol
515
515
52-wk High
$15.56
$15.56
52-wk Low
$4.22
$4.22
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Christopher Gleeson |
62 | 2011 | Chairman of the Board |
Hany Massarany |
50 | 2011 | President, Chief Executive Officer, Director |
Richard Slansky |
55 | 2012 | Chief Financial Officer |
Matthew Cohen |
40 | 2011 | Senior Vice President, General Counsel, Corporate Secretary |
Michael Gleeson |
37 | 2012 | Senior Vice President - Sales |
Jeffrey Hawkins |
34 | 2010 | Senior Vice President - Marketing and Business Development |
Jennifer Williams |
39 | 2010 | Senior Vice President - Global Operations & Human Resources |
Jorge Garces |
40 | 2012 | Senior Vice President - Research and Development |
Jon Kayyem |
48 | 2011 | Chief Scientific Officer |
Daryl Faulkner |
63 | 2010 | Independent Director |
James Fox |
2010 | Independent Director | |
Kevin O'Boyle |
56 | 2010 | Independent Director |
Stephen Worland |
53 | 2012 | Independent Director |
Biographies
| Name | Description |
|---|---|
Christopher Gleeson |
Mr. Christopher M. Gleeson is Chairman of the Board of GenMark Diagnostics, Inc. He has served as Chairman of the Board of the Company since March 2010, and served as Chief Executive Officer of the Company on an interim basis from August 2010 to May 2011. Additionally, from December 1, 2010 through May 1, 2011, Mr. Gleeson served as the Company’s principal financial officer. Mr. Gleeson has served as Chairman of the Board of Osmetech plc since July 2009. Mr. Gleeson was formerly President, Chief Executive Officer and a Director of Ventana Medical Systems, Inc., a supplier of automated diagnostic systems to the anatomical pathology market where he served from 1999 to February 2008. Following the acquisition of Ventana by Roche Diagnostics in February 2008, Mr. Gleeson became a member of the board of directors of Roche Diagnostics. Prior to joining Ventana, Mr. Gleeson was Senior Vice-President of Bayer Diagnostics, the diagnostics division of Bayer Healthcare Pharmaceuticals and general manager of the U.S. commercial operations for Chiron Diagnostics, the diagnostics division of Chiron Corporation. Prior to that time, he was the founder, owner, and managing director of Australian Diagnostics Corporation. Mr. Gleeson attended the Pharmacy and Business Schools at Monash University in Australia. |
Hany Massarany |
Mr. Hany Massarany serves as the President, Chief Executive Officer, Director of GenMark Diagnostics Inc., since May 2011. From February 2009 to April 2011, Mr. Massarany served as President of Ventana Medical Systems, a supplier of automated diagnostic systems to the anatomical pathology market, and Head of Roche Tissue Diagnostics, a division of F. Roche Hoffman-La Roche Ltd. focusing manufacturing instruments and reagents that automate tissue processing and slide staining diagnostics for cancer. From 1999 to 2009, he held various global leadership positions with Ventana, including Chief Operating Officer, Executive Vice President Worldwide Operations, Senior Vice President Corporate Strategy and Development, and Vice President North American Commercial Operations. Prior to Ventana, Mr. Massarany held executive management positions with Bayer Diagnostics and Chiron Diagnostics, working in both Asia Pacific and the United States. Mr. Massarany received a B.S. degree in Microbiology and Immunology from Monash University, Australia and an MBA from Melbourne University, Australia. |
Richard Slansky |
Mr. Richard B. Slansky serves as Chief Financial Officer of Genmark Diagnostics, Inc., since April 23, 2012. Prior to joining the Company, Mr. Slansky served as Chief Financial Officer of Digirad Corporation from March 2009 to April 2012. Mr. Slansky previously served as President, Chief Financial Officer, Director, and Corporate Secretary of SpaceDev Inc., a publicly held space technology and aerospace company. Mr. Slansky joined SpaceDev Inc. in February 2003 as Chief Financial Officer and Corporate Secretary. In November 2004, Mr. Slansky was appointed as President and Director of SpaceDev Inc. Mr. Slansky served as interim Chief Executive Officer, interim Chief Financial Officer, and Director for Quick Strike Resources, Inc., an IT training, services, and consulting firm, from July 2002 to February 2003. From May 2000 to July 2002, Mr. Slansky served as Chief Financial Officer, Vice President of Finance, Administration and Operations, and Corporate Secretary for Path 1 Network Technologies Inc., a public company focused on merging broadcast and cable quality video transport with IP networks. Mr. Slansky earned a bachelor’s degree in economics and science from the University of Pennsylvania’s Wharton School of Business and a master’s degree in business administration in finance and accounting from the University of Arizona. |
Matthew Cohen |
Mr. Matthew R. Cohen, Esq., is Senior Vice President, General Counsel, Corporate Secretary of GenMark Diagnostics Inc., since November 2011. From January 2005 until November 2011, he was a member of the legal department of Genentech, Inc., a biotechnology company and member of the Roche Group as of March 2009, most recently serving as Associate General Counsel and practice group lead of Genentech’s business development and alliance management functions. During Mr. Cohen’s time at Genentech, he also oversaw legal support of Genentech’s Corporate Information Technology organization and research contracting group. Prior to joining Genentech, he was a Special Counsel in the Sydney, Australia office of Minter Ellison, and an associate with the law firms Kirkland & Ellis in New York, N.Y. and Foley & Lardner in Washington, D.C. Mr. Cohen is a registered patent attorney with the United States Patent and Trademark Office, and in 1997 was a fellow of the Max-Planck-Institute for Foreign and International Patent, Copyright and Competition Law in Munich, Germany. Mr. Cohen received his B.S. in Chemistry from Emory University and J.D. from the George Washington School of Law. |
Michael Gleeson |
Mr. Michael Gleeson is Senior Vice President - Sales of GenMark Diagnostics Inc., since March 2012. Prior to that, he held the position of Vice President, U.S. Sales from November 2010 to March 2012. From May 2010 to November 2010 he served as National Sales Director for the Company and in the same capacity for Osmetech Technology, Inc, a wholly-owned subsidiary of Osmetech plc, since November 2009. Mr. Gleeson has 15 years of experience in Director & Senior Sales Executive roles with both public and privately held companies in the enterprise software and services sector. Before joining the Company, he served as Senior Executive with Sybase (an SAP company), an industry in delivering enterprise and mobile software to manage, analyze and mobilize information from February 2009 to November 2009 and as Director, Financial Services with GuardianEdge Technologies (acquired by Symantec) from February 2006 to November 2008. Mr. Gleeson also held positions with BEA Systems (acquired by Oracle) and Cap Gemini Ernst & Young where he had responsibility in global sales, ISV, OEM and channel sales. Mr. Gleeson holds a B.S. degree in Entrepreneurial Studies from Babson College in Massachusetts. |
Jeffrey Hawkins |
Mr. Jeffrey Hawkins is Senior Vice President - Marketing and Business Development of GenMark Diagnostics, Inc., since November 2010. Prior to that, from May 2010 to November 2010 he held the position of Vice President of Business Development and in the same capacity for Osmetech Technology, Inc, a wholly-owned subsidiary of Osmetech plc, from March 2010 to May 2010 and as Vice President of Marketing from December 2009 to March 2010. From July 2008 until December 2009, Mr. Hawkins was Executive Director of Laboratory Marketing for Hologic, Inc., a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products. From November 2006 until its acquisition by Hologic in June 2008, Mr. Hawkins served as Executive Director of Marketing of Third Wave Technologies Inc., a provider of DNA and RNA analysis products to clinical, research and agricultural customers. Prior to Third Wave, Mr. Hawkins has held various positions of increasing responsibility in the areas of Marketing, Product Development and Operations for Sysmex America and Abbott Laboratories. Mr. Hawkins is currently a member of the board of directors for Ohmx Corporation, a bioelectronic detection company developing a monitoring device to be used in all point-of-care (POC) settings. Mr. Hawkins received a B.A. in Chemistry with honors from Concordia University and a master’s degree in business administration from Keller Graduate School of Management. |
Jennifer Williams |
Ms. Jennifer Williams is Senior Vice President - Global Operations & Human Resources of GenMark Diagnostics, Inc. Prior to joining the Company, she held the position of Senior Human Resource Executive with Cerberus Operations and Advisory Company, a private equity firm, from February 2008 to May 2010, responsible for human resources oversight and transformation of global companies in the portfolio. From January 2005 to January 2008, she served as Vice President Human Resources at HD Supply, a wholesale distribution company serving the infrastructure, construction, and maintenance markets, initially as part of The Home Depot organization and subsequently spun off in 2007. Previous to that, she led Talent Management for The Home Depot including organization design, succession planning, leadership programs, and executive development. Ms. Williams began her career at Honeywell (formerly AlliedSignal) and held positions of increasing responsibility in Quality, Operations, Program Management, and Organization Effectiveness. Ms. Williams holds a master’s degree in business administration from Case Western Reserve in Organizational Behavior and an undergraduate degree in Industrial and Operations Engineering from the University of Michigan. Ms. Williams holds a certification in Organization Design and is a Six Sigma greenbelt. |
Jorge Garces |
Dr. Jorge A. Garces serves as Senior Vice President - Research and Development of GenMark Diagnostics, Inc., since February 13, 2012. Prior to joining the Company, from October 2009 to February 2012 Dr. Garces served as Chief Executive Officer and President of the Enigma Diagnostics US business, a company that develops rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Prior to Enigma Diagnostics, from July 2008 to October 2009 Dr. Garces served as Vice President of R&D and Site Operations Manager at Hologic, Inc., a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products, where he managed the R&D, Clinical and Manufacturing business unit in Madison, WI, and led the development and submission to FDA for approval of their Cystic Fibrosis and HPV products. Additionally, from October 2005 to July 2008 Dr. Garces held the role of Senior Vice President of Research and Development at Third Wave Technologies Inc., a provider of DNA and RNA analysis products to clinical, research and agricultural customers. Earlier in his career Dr. Garces held positions at Genzyme Genetics and Athena Diagnostics, Inc. Dr. Garces earned his B.S. in Biology from Brooklyn College and his doctorate in Cell and Molecular Biology from the City University of New York. He completed his post-doctoral training at the University of Massachusetts Medical School and received a master’s degree in business administration from the Kellogg Graduate School of Management. |
Jon Kayyem |
Dr. Jon Faiz Kayyem, Ph.D., serves as Chief Scientific Officer of GenMark Diagnostics Inc. He was appointed Chief Scientific Officer of the Company in August 2010. Dr. Kayyem served as President and Chief Executive Officer of the Company from May 2010 to August 2010. From August 2009 to May 2010, Dr. Kayyem served as President and Chief Executive Officer of Osmetech plc and Chairman of the board of directors of Osmetech plc from January 2009 to August 2009. Dr. Kayyem attended Yale University and received a combined M.S. and B.S. in Molecular Biophysics and Biochemistry in 1985. He received his Ph.D. in Molecular Biology in 1991 at The California Institute of Technology (“Caltech”). Dr. Kayyem remained at Caltech as a Senior Research Fellow until 1995, when he founded Clinical Micro Sensors to commercialize technical innovations he developed while at Caltech. In 2000, Clinical Micro Sensors was sold to Motorola, Inc., and subsequently purchased by Osmetech plc in 2005. In 2004, Dr. Kayyem left Clinical Micro Sensors and co-founded the biotechnology fund management company, Efficacy Capital Limited, where he served as managing partner until September 2009. |
Daryl Faulkner |
Mr. Daryl Jay Faulkner is Independent Director of GenMark Diagnostics Inc., since March 2010. Mr. Faulkner was appointed to the board of directors of Osmetech plc in August 2008, serving as Non-Executive Chairman until December 2008. Mr. Faulkner is currently a member of the board of directors of AspenBio Pharma, an emerging biotechnology company engaged in the research, development, manufacture, and licensing of novel diagnostics and drugs. Mr. Faulkner also served as Executive Chair and Interim Chief Executive Officer of AspenBio Pharma from February 2009 until March 2010. From August 2008 to January 2009, Mr. Faulkner served as a consultant to Qiagen NV, a provider of innovative sample and assay technologies and products, in connection with its integration of Digene Corp., a developer of gene-based diagnostic tests acquired by Qiagen in August 2007. Mr. Faulkner had served as President and Chief Executive Officer and a director of Digene from December 2006 until consummation of Qiagen’s acquisition of Digene in August 2007. From 1998 until March 2006, Mr. Faulkner served in several executive roles at Invitrogen Corp., a life sciences company, including Senior Vice President, Business Segment Management from 2003 until March 2006. Mr. Faulkner received a B.S. in Industrial Relations from the University of North Carolina, Chapel Hill and an M.A. in Business Management from Webster University. |
James Fox |
Dr. James Charles Fox, Ph.D., serves as Independent Director of GenMark Diagnostics, Inc., since September 1, 2010. Dr. Fox has experience in global technology and healthcare businesses. He led the start up of Invetech, an Australian contract research and development company that specializes in healthcare products and complex instruments for international markets. Invetech was merged with Australian Securities Exchange listed Vision Systems Limited in 1993, and Dr. Fox took over as Group Managing Director of the combined entity. In January 2007, Vision Systems Ltd., then a global cancer diagnostics company, was acquired by Danaher Corporation. Prior to Invetech, Dr. Fox spent seven years working as a consultant and director with PA Technology. Dr. Fox currently serves as Chairman of the Board of Biota Holdings Limited, a director of Air New Zealand Ltd., a director of TTP Group plc and as a director of MS Research Australia, a not-for-profit organization aimed at financing public multiple sclerosis research. Dr. Fox received his Bachelor’s, Master’s and Ph.D. degrees in engineering from the University of Melbourne. |
Kevin O'Boyle |
Mr. Kevin C. O'Boyle, CPA, is Independent Director of GenMark Diagnostics Inc., since March 2010. Since December of 2010, Mr. O’Boyle has served as Senior Vice President and Chief Financial Officer and was subsequently promoted to Senior Vice President of Business Operations at Advanced BioHealing, Inc., a medical device company. From January 2003 until December 2009, Mr. O’Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company that completed its initial public offering in May 2004. Prior to that time, Mr. O’Boyle served in various positions during his six years with ChromaVision Medical Systems, Inc., a publicly held medical device company specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Mr. O’Boyle also held various positions during his seven years with Albert Fisher North America, Inc., a publicly held international food company, including Chief Financial Officer and Senior Vice President of Operations. He currently serves on the boards of Tornier N.V., a global orthopedics company, and Zeltiq Aesthetics, Inc., both publicly traded companies. Mr. O’Boyle is a Certified Public Accountant and received a Bachelor of Science in Accounting from the Rochester Institute of Technology and completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School. |
Stephen Worland |
Dr. Stephen T. Worland, Ph.D. has been appointed as Independent Director of GenMark Diagnostics, Inc., effective June 13, 2012. He has experience in global technology, infectious disease and healthcare businesses and is currently President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a start-up stage company focused on new treatments for cancer. Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for Hepatitis C and cancer, from August 2007 until the company's acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named CEO, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career in 1988 at Agouron Pharmaceuticals, Inc. and remained with the company through its commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period he held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. He received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Christopher Gleeson |
18,344 |
Hany Massarany |
2,028,310 |
Richard Slansky |
-- |
Matthew Cohen |
-- |
Michael Gleeson |
-- |
Jeffrey Hawkins |
396,435 |
Jennifer Williams |
424,323 |
Jorge Garces |
-- |
Jon Kayyem |
413,468 |
Daryl Faulkner |
-- |
James Fox |
-- |
Kevin O'Boyle |
-- |
Stephen Worland |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Christopher Gleeson |
0 | 0 |
Hany Massarany |
0 | 0 |
Richard Slansky |
0 | 0 |
Matthew Cohen |
0 | 0 |
Michael Gleeson |
0 | 0 |
Jeffrey Hawkins |
0 | 0 |
Jennifer Williams |
0 | 0 |
Jorge Garces |
0 | 0 |
Jon Kayyem |
0 | 0 |
Daryl Faulkner |
0 | 0 |
James Fox |
0 | 0 |
Kevin O'Boyle |
0 | 0 |
Stephen Worland |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
SLANSKY RICHARD B |
15,000 | $0.00 |
CHAKRAVARTY INGO |
25,000 | $0.00 |
KAYYEM JON FAIZ |
6,000 | $12.93 |
GLEESON CHRISTOPHER MICHAEL |
16,000 | $11.56 |
GLEESON CHRISTOPHER MICHAEL |
17,000 | $11.80 |
GLEESON MICHAEL |
6,723 | $11.92 |
GLEESON MICHAEL |
10,000 | $12.00 |
GLEESON CHRISTOPHER MICHAEL |
17,000 | $11.93 |
KAYYEM JON FAIZ |
4,352 | $11.88 |
GARCES JORGE A |
4,033 | $11.88 |
HAWKINS JEFFREY ALAN |
3,794 | $11.88 |
WILLIAMS JENNIFER ANNE |
18,351 | $12.50 |
HAWKINS JEFFREY ALAN |
18,000 | $0.00 |
SLANSKY RICHARD B |
21,624 | $0.00 |
GARCES JORGE A |
18,000 | $0.00 |
WILLIAMS JENNIFER ANNE |
30,190 | $0.00 |
KAYYEM JON FAIZ |
19,053 | $0.00 |
MASSARANY HANY |
81,457 | $0.00 |
GLEESON MICHAEL |
29,152 | $0.00 |
HAWKINS JEFFREY ALAN |
79 | $11.09 |
WILLIAMS JENNIFER ANNE |
164 | $9.47 |
HAWKINS JEFFREY ALAN |
80 | $9.47 |
GLEESON CHRISTOPHER MICHAEL |
1,044,897 | $0.00 |
WILLIAMS JENNIFER ANNE |
135 | $9.93 |
HAWKINS JEFFREY ALAN |
66 | $9.93 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
